Press coverage about GlycoMimetics (NASDAQ:GLYC) has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GlycoMimetics earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the company’s share price in the next few days.
Shares of GlycoMimetics (GLYC) traded up 1.83% during mid-day trading on Tuesday, reaching $12.25. 853,072 shares of the company were exchanged. The firm’s market capitalization is $301.84 million. GlycoMimetics has a 12 month low of $3.82 and a 12 month high of $16.94. The company’s 50 day moving average price is $9.32 and its 200 day moving average price is $6.72.
GlycoMimetics (NASDAQ:GLYC) last released its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. Equities analysts anticipate that GlycoMimetics will post ($1.41) earnings per share for the current year.
A number of equities analysts recently commented on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $13.00 target price on shares of GlycoMimetics in a research note on Tuesday, June 6th. Jefferies Group LLC reduced their target price on shares of GlycoMimetics from $16.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday, June 6th. ValuEngine raised shares of GlycoMimetics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Cowen and Company reaffirmed an “outperform” rating on shares of GlycoMimetics in a report on Sunday, May 28th. Finally, Canaccord Genuity reissued a “buy” rating and set a $12.00 price target on shares of GlycoMimetics in a report on Friday, May 19th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. GlycoMimetics presently has a consensus rating of “Buy” and a consensus target price of $10.95.
COPYRIGHT VIOLATION WARNING: This piece was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://sportsperspectives.com/2017/06/20/glycomimetics-glyc-earns-media-sentiment-score-of-0-06-updated-updated-updated-updated.html.
In related news, SVP Helen M. Thackray sold 2,000 shares of the stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $15.57, for a total value of $31,140.00. Following the completion of the sale, the senior vice president now directly owns 152,615 shares of the company’s stock, valued at approximately $2,376,215.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 43.80% of the company’s stock.
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
Receive News & Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.